

Resource Summary Report

Generated by [RRID](#) on Aug 3, 2026

BIU-87

RRID:CVCL_6881

Type: Cell Line

Proper Citation

RRID:CVCL_6881

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_6881

Proper Citation: RRID:CVCL_6881

Description: Cell line BIU-87 is a Undefined cell line type with a species of origin Unidentified organism (Unknown organism)

Sex: Sex unspecified

Defining Citation: [PMID:9594332](#), [PMID:23618585](#), [PMID:26116706](#), [PMID:30967374](#)

Comments: Problematic cell line: Misidentified/contaminated. Seems to be contaminated by non-human cells (PubMed=26116706). Originally thought to originate from a 58 year old male patient with an urinary bladder carcinoma..

Category: Undefined cell line type

Organism: Unidentified organism (Unknown organism)

Name: BIU-87

Synonyms: BIU87

Cross References: CCTCC:GDC0120, KCB:KCB 2006103YJ, Wikidata:Q28658473

ID: CVCL_6881

Record Creation Time: 20220427T215403+0000

Record Last Update: 20260802T010336+0000

Ratings and Alerts

No rating or validation information has been found for BIU-87.

Warning: Problematic cell line: Misidentified/contaminated. Seems to be contaminated by non-human cells (PubMed=26116706). Originally thought to originate from a male patient with an urinary bladder carcinoma.

Problematic cell line: Misidentified/contaminated. Seems to be contaminated by non-human cells (PubMed=26116706). Originally thought to originate from a 58 year old male patient with an urinary bladder carcinoma..

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 2 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Wang Y, et al. (2022) Development of Novel Aptamer-Based Targeted Chemotherapy for Bladder Cancer. Cancer research, 82(6), 1128.

Wu Z, et al. (2022) Adeno-associated virus-delivered alpha synuclein inhibits bladder cancer growth via the p53/p21 signaling pathway. Cancer gene therapy, 29(8-9), 1193.